“Marc Beer’s women’s health startup raises $42 million “

Women around the world suffer from numerous health conditions that severely affect the quality of life that they live. Sadly, some of these medical conditions have been neglected by the biopharma companies for one reason or another. One man, Marc Beer, an experienced executive in the pharmaceutical sector and entrepreneur is looking to change the current situation in women’s health care. Through his biopharma start-up Renovia – based in Boston – Marc is looking to finding medical solutions to some of the most chronic health issues faced by women around the world.

 

Raising funds for the course

 

Recently, Marc Beer was out and about rallying for funds to further the good course of his start-up looking to not only improve women’s health but also bring happiness to communities. In his funds rallying campaign, Marc was very successful. He managed to raise a total of $42 million in funding to finance Renovia’s operations. The main focus for the company of late has been finding therapeutic and diagnostic solutions for the notorious pelvic floor disorders especially urinary incontinence. Reliable statistics indicate that not less than 250 million women from around the globe suffer from this dreaded condition.

 

The Renovia CEO raised a total of $32 million through Series B funding, and the additional $10 million came from venture debt. Marc Beer successfully got on board some of the most seasoned health sector investors in his Series B round funding to raise the $32 million. A healthcare-focused investment firm, Longwood Fund which had also earlier invested in Renovia was part of the Series B round. Other investors were Ascension Ventures from Missouri and Perspective Advisors from New York.

 

The funding raised will be dedicated to coming up with the second generation of the Leva devices. Additionally, there are three other break-through devices in the works at Renovia which these funds will play a significant role in their development. Making this funding announcement, Marc Beer mentioned that his company was very grateful for the support of its investors. He added that his company would keep delivering new treatments for pelvic disorders as their knowledge on it expands through research.

 

About Marc Beer

 

Marc Beer is the co-founder and Chief Executive Officer of the Boston based biopharma start-up Renovia. This pharmaceutical entrepreneur has over two decades of experience as an executive in the medical sector. Marc’s area of specialization has been the development and commercialization of break-through biotechnology devices and pharmaceutical diagnostics. Through his start-up Renovia, Marc hopes to help millions of women around the world living with pelvic disorders live normal lives. The Leva device (first edition) has significantly made this possible, and he hopes with its second edition things will even get better. Learn more: https://patch.com/massachusetts/boston/renovias-marc-beer-raises-42m-treat-womens-health-issues

 

Jeff Aronin: A Pioneer in the Biotechnology Sector

Paragon Biosciences is a company that invests in innovative biotechnology companies. The goal of Paragon is to build up companies that can discover treatments for rare and previously untreatable diseases. Paragon has had 13 new drugs approved by the FDA in the past 10 years. Some of the investment partners for Paragon include Fidelity Investments, Diaderm, Debra Austria, and Valor Equity Partners.

Castle Creek Pharmaceuticals (CCP) is a Paragon portfolio company specializing in finding treatments for rare dermatologic diseases. The company has created numerous innovative drugs and therapies that have the potential to treat many of these diseases.

Harmony Biosciences is another portfolio company dedicated to finding cures and treatments for patients with sleep and central nervous system problems.

Jeff Aronin assumed the role of Chairman and CEO of Paragon Biosciences in 2010. He also is the chairman of several successful Paragon portfolio companies. Jeff Aronin founded Ovation Pharmaceuticals in 2000 and served as that company’s president and CEO until 2009. Lundbeck, Inc. acquired Ovation Pharmaceuticals in 2009 and Jeff Aronin stayed on as the CEO and president during the merger. Jeff Aronin has over 20 years of experience in creating biotechnology companies (Reporterexpert). He is highly respected in the bioscience industry because of his vast contributions and knowledge. Jeff also mentors aspiring entrepreneurs in the field.

Jeff Aronin is dedicated to philanthropy and supports numerous non-profit organizations such as the Susan G. Komen Foundation, the Liver Life Challenge, Juvenile Diabetes, the Teaching Tolerance, the Jewish United Fund, the Boys and Girls Club of Chicago, and the Chicago Parks Foundation.

Jeff has also received countless awards throughout his career that include: the 2017 Weizmann Leadership Award, Buyouts Magazine “Deal of the year in 2010,” Epilepsy Foundation of Chicago Rovner Award in 2007, and the Holocaust Museum and Education Center’s Humanitarian Award in 2010. Despite his success, Jeff Aronin will not be satisfied until treatments are found for all untreatable diseases.